HER2-low status may predict poor neoadjuvant chemotherapy response in HR-negative breast cancer: a real-world multicenter study.
Weiwei XuYunshan JiangLingyun XuChangwen LiJi WangZhao LiuDandan XueYanlin GuZhaoyun ZhongShiqing HeShui WangWenbin ZhouHong PanPublished in: Japanese journal of clinical oncology (2023)
Our results demonstrate that human epidermal growth factor receptor 2-low tumors achieved a significantly lower pathological complete response rate with conventional chemotherapy than those with human epidermal growth factor receptor 2-zero tumors, especially for hormone receptor-negative group. Large, randomized, prospective studies are needed to confirm our data and further evaluate the prognostic value of human epidermal growth factor receptor 2-low expression.
Keyphrases
- epidermal growth factor receptor
- tyrosine kinase
- advanced non small cell lung cancer
- endothelial cells
- neoadjuvant chemotherapy
- induced pluripotent stem cells
- locally advanced
- squamous cell carcinoma
- lymph node
- clinical trial
- open label
- double blind
- early stage
- electronic health record
- rectal cancer
- placebo controlled
- sentinel lymph node
- chemotherapy induced